Release Testing For Gene Therapy Market Size In 2026: Regional Growth, Key Segments And Future Outlook
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Release Testing For Gene Therapy Market Growth From $1.67 Billion In 2026 To $3.08 Billion By 2030 At A CAGR Of 16.5%
The market size for release testing in gene therapy has seen substantial growth in recent years. It is projected to expand from $1.43 billion in 2025 to $1.67 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 16.3%. The expansion observed in past periods is attributable to an increase in gene therapy trials, strict regulatory quality standards, enhanced viral vector production, the proliferation of biologics testing laboratories, and a rise in advanced therapy approvals.
The market for release testing in gene therapy is projected to experience swift expansion over the coming years. This market is anticipated to reach a value of $3.08 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 16.5%. Key drivers for this growth during the projected timeframe include the proliferation of commercial gene therapies, an escalating need for rapid release testing, the widening scope of contract testing services, heightened regulatory scrutiny, and the integration of automated qc platforms. Significant trends anticipated within this forecast period encompass high sensitivity potency assays, swift sterility testing platforms, automated batch release analytics, comprehensive multi parameter quality control panels, and sophisticated vector identity testing.
Get A Free Sample Report With In-Depth Market Insights:
Release Testing For Gene Therapy Market Growth Catalysts And Demand Drivers
The anticipated expansion of global approvals for gene therapies is projected to fuel the growth of the release testing for gene therapy market in the future. Gene therapies are therapeutic approaches that entail introducing, extracting, or altering genetic material in a patient’s cells to manage or avert illnesses. This increase in worldwide gene therapy approvals is underpinned by greater regulatory acceptance, scientific progress, and a growing need for novel treatments for genetic conditions that were previously unmanageable. Release testing for gene therapy constitutes a mandatory regulatory step, guaranteeing product quality and patient well-being via evaluations of potency, purity, identity, and safety before a batch is cleared. As an illustration, the National Center for Biotechnology Information, a U.S.-based governmental research resource, reported in November 2023 that over 100 gene, cell, and ribonucleic acid (RNA) therapies had received global approval by early 2023, with an additional over 3,700 therapies currently in clinical and preclinical stages of development. Consequently, the rising volume of global gene therapy approvals is poised to contribute significantly to the expansion of the release testing for gene therapy market.
Release Testing For Gene Therapy Market Segment Breakdown: Which Categories Lead On Revenue?
The release testing for gene therapy market covered in this report is segmented –
1) By Test Type: Potency Testing; Purity Testing; Identity Testing; Safety Testing; Sterility Testing; Other Test Types
2) By Product Type: Assay Kits; Reagents; Instruments; Services
3) By Therapy Type: In Vivo Gene Therapy; Ex Vivo Gene Therapy
4) By Application: Clinical Diagnostics; Research; Quality Control; Process Development; Other Applications
5) By End-User: Pharmaceutical and Biotechnology Companies; Academic and Research Institutes; Contract Research Organizations; Other End-Users
Subsegments:
1) By Potency Testing: Functional Activity Assays; Gene Expression Level Measurement; Biological Activity Evaluation; Dose Response Assessment
2) By Purity Testing: Residual Host Cell Protein Analysis; Residual Deoxyribonucleic Acid Quantification; Process Related Impurity Testing; Product Related Impurity Assessment
3) By Identity Testing: Genetic Sequence Confirmation; Vector Identity Verification; Transgene Identity Analysis; Cell Line Authentication
4) By Safety Testing: Adventitious Agent Testing; Replication Competent Virus Detection; Endotoxin Level Evaluation; Toxicity Assessment
5) By Sterility Testing: Bacterial Contamination Testing; Fungal Contamination Testing; Mycoplasma Detection; Environmental Monitoring Validation
6) By Other Test Types: Stability Testing; Packaging Integrity Testing; Shelf Life Determination; Transport and Storage Condition Testing
Release Testing For Gene Therapy Market Trends Shaping Long-Term Demand
Leading companies in the release testing for gene therapy market are concentrating on developing inventive solutions, such as digital PCR-based analytical testing platforms. This initiative addresses the increasing demand for highly accurate, sensitive, and standardized methodologies essential for guaranteeing product safety, potency, and regulatory adherence for complex gene therapy products. Digital polymerase chain reaction (PCR)-based analytical testing platforms are sophisticated molecular systems that precisely quantify deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) by separating samples into thousands of individual reactions, thereby enabling highly sensitive and absolute measurement of nucleic acid targets. For instance, in April 2025, QIAGEN N.V., a Germany-based supplier of molecular diagnostics and life science tools, expanded its QIAcuity digital PCR portfolio with new lentivirus solutions crafted to enhance quality control in cell and gene therapy manufacturing. These additions support viral vector genome titration, vector copy number determination, and replication-competent lentivirus detection, facilitating high-precision analytics for process development, batch release, and regulatory compliance. The platform offers absolute quantification across singleplex and multiplex applications, strong repeatability, and specialized kits for critical gene therapy vectors, delivering more reliable and reproducible results than many conventional testing approaches.
Release Testing For Gene Therapy Market Leading Players And Competitive Positioning
Major companies operating in the release testing for gene therapy market are Thermo Fisher Scientific Inc., Boehringer Ingelheim BioXcellence GmbH, Fujifilm Diosynth Biotechnologies Inc., AGC Biologics Inc., SGS SA, Lonza Group AG, Eurofins Scientific SE, WuXi AppTec Co. Ltd., Charles River Laboratories International Inc., Sartorius AG, Samsung Biologics Co. Ltd., Bio-Rad Laboratories Inc., Pace Analytical Services LLC, KBI Biopharma Inc., BioAgilytix Labs LLC, Viralgen Vector S.L., GenScript ProBio LLC, KCAS Bioanalytical Services, Creative Biolabs LLC, Cellipont Bioservices Inc.
View The Full Release Testing For Gene Therapy Market Report:
Release Testing For Gene Therapy Market Regional Split: Which Areas Are Fueling Growth?
North America was the largest region in the release testing for gene therapy in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the release testing for gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
